Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston, TX 77030, USA.
Department of Translational Medical Sciences, Texas A&M Health Science Center, Houston, TX 77030, USA.
Cells. 2022 Mar 18;11(6):1033. doi: 10.3390/cells11061033.
Early identification and management of precancerous lesions at high risk of developing cancers is the most effective and economical way to reduce the incidence, mortality, and morbidity of cancers as well as minimizing treatment-related complications, including pain, impaired functions, and disfiguration. Reliable cancer-risk-predictive markers play an important role in enabling evidence-based decision making as well as providing mechanistic insight into the malignant conversion of precancerous lesions. The focus of this article is to review updates on markers that may predict the risk of oral premalignant lesions (OPLs) in developing into oral squamous cell carcinomas (OSCCs), which can logically be discovered only by prospective or retrospective longitudinal studies that analyze pre-progression OPL samples with long-term follow-up outcomes. These risk-predictive markers are different from those that prognosticate the survival outcome of cancers after they have been diagnosed and treated, or those that differentiate between different lesion types and stages. Up-to-date knowledge on cancer-risk-predictive markers discovered by longitudinally followed studies will be reviewed. The goal of this endeavor is to use this information as a starting point to address some key challenges limiting our progress in this area in the hope of achieving effective translation of research discoveries into new clinical interventions.
早期识别和管理有发展为癌症高风险的癌前病变是降低癌症发病率、死亡率和发病率以及最小化治疗相关并发症(包括疼痛、功能障碍和畸形)的最有效和经济的方法。可靠的癌症风险预测标志物在基于证据的决策中发挥着重要作用,并为癌前病变恶性转化的机制提供了深入了解。本文的重点是回顾可能预测口腔黏膜潜在恶性病变(OPL)发展为口腔鳞状细胞癌(OSCC)风险的标志物的最新进展,这些标志物只能通过前瞻性或回顾性纵向研究来发现,这些研究分析了具有长期随访结果的前进展 OPL 样本。这些风险预测标志物与那些预测癌症诊断和治疗后生存结果的标志物不同,也与区分不同病变类型和阶段的标志物不同。本文将回顾通过纵向随访研究发现的癌症风险预测标志物的最新知识。这项工作的目标是利用这些信息作为起点,解决一些限制我们在这一领域取得进展的关键挑战,希望将研究发现有效地转化为新的临床干预措施。